{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:38:39Z","timestamp":1789799919584,"version":"4.0.1"},"reference-count":50,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Cystic fibrosis transmembrane conductance regulator modulator (mCFTR) therapy has been proven efficacious in controlled clinical trials for individuals with cystic fibrosis. This post-approval retrospective study aimed to determine the comprehensive effects of elexacaftor\/tezacaftor\/ivacaftor (ETI) on nutritional status, the respiratory system and quality of life over 12 months of clinical use in paediatric patients treatment-na\u00efve to mCFTR. Methods: A retrospective analysis of records of CF adolescents on ETI therapy was conducted. The selected parameters of anthropometric measurements, body composition assessed by BIA, spirometry, and multiple breath nitrogen washout (MBNW) to measure lung clearance index (LCI), were evaluated before therapy and at 3 and 12 months after treatment initiation. Additionally, children completed the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Results: Over 18 months, data from 58 patients (mean age 14.34 \u00b1 1.70, 50% female; 43% homozygous F508del) on ETI were collected. Body weight increased significantly over 12 months, with a mean gain of 3.33 kg at 3 months (p &lt; 0.001) and 7.10 kg at 12 months (p &lt; 0.001), alongside improvements in BMI z-score, fat-free mass, and fat mass. Significant changes (p &lt; 0.001) were also observed after 3 and 12 months in ppFEV1 (8.91 \u00b1 8.23; 9.67 \u00b1 8.77) and ppFVC (4.46 \u00b1 5.24; 4.61 \u00b1 5.70), with a decrease in LCI (\u22121.62 \u00b1\u00a02.15; \u22121.68 \u00b1 1.89). The CFQ-R Respiratory score increased by 11.75 points and correlated with most of the pulmonary and nutritional parameters. Conclusions: In real-world settings, clinical improvement during ETI therapy reflects a comprehensive impact on nutritional status, body composition, pulmonary function, and quality of life for adolescents with CF.<\/jats:p>","DOI":"10.3390\/jcm14227969","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T17:45:34Z","timestamp":1762796734000},"page":"7969","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive Evaluation of Elexacaftor\/Tezacaftor\/Ivacaftor in Paediatric Cystic Fibrosis: Nutritional, Pulmonary, and Quality-of-Life Outcomes"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6496-8737","authenticated-orcid":false,"given":"Katarzyna","family":"Walicka-Serzysko","sequence":"first","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-3316","authenticated-orcid":false,"given":"Magdalena","family":"Postek","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-1848","authenticated-orcid":false,"given":"Monika","family":"Mielus","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Borawska-Kowalczyk","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3365-9963","authenticated-orcid":false,"given":"Justyna","family":"Milczewska","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Zybert","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8702-3808","authenticated-orcid":false,"given":"\u0141ukasz","family":"Wozniacki","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wo\u0142kowicz","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Sands","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland"},{"name":"Cystic Fibrosis Centre, Paediatric Hospital, 05-092 Dziekan\u00f3w Le\u015bny, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): A phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"863280","DOI":"10.3389\/fphar.2022.863280","article-title":"Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dagenais, R.V.E., Su, V.C.H., and Quon, B.S. (2020). Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010023"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1176815","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102247","DOI":"10.1016\/j.pupt.2023.102247","article-title":"Real world outcomes of CFTR modulator therapy in Australian adults and children","volume":"82","author":"Kuek","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kapouni, N., Moustaki, M., Douros, K., and Loukou, I. (2023). Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. Children, 10.","DOI":"10.3390\/children10030554"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: Real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_17","first-page":"146","article-title":"Utilization of patient-reported outcomes as a step towards collaborative medicine","volume":"14","author":"Blackwell","year":"2013","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: The 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Walicka-Serzysko, K., Borawska-Kowalczyk, U., Postek, M., Milczewska, J., Zybert, K., Wo\u017aniacki, \u0141., Mielus, M., Wo\u0142kowicz, A., \u017babi\u0144ska-Jaro\u0144, A., and Matusiak, J. (2024, January 5\u20138). Real-life impact of CFTR modulator therapy on respiratory system in children with cystic fibrosis. Proceedings of the 47th European Cystic Fibrosis Conference, Glasgow, UK.","DOI":"10.1016\/S1569-1993(24)00414-4"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report","volume":"153","author":"Farrell","year":"2008","journal-title":"J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/thx.2005.043539","article-title":"Cystic fibrosis: Terminology and diagnostic algorithms","volume":"61","author":"Wilschanski","year":"2006","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_23","unstructured":"(2025, August 25). Available online: https:\/\/www.ecfs.eu\/sites\/default\/files\/VariablesDefinitionsAS_V9_ECFSPR_20241121.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zapletal, A., Samanek, M., and Paul, T. (1987). Lung Function in Children and Adolescents: Methods, Reference Values, Karger.","DOI":"10.1159\/isbn.978-3-318-04125-5"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1164\/rccm.200605-642ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Pulmonary function testing in preschool children","volume":"175","author":"Beydon","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0031-3939(09)70151-9","article-title":"Polska adaptacja Kwestionariusza Jako\u015bci \u017bycia przeznaczonego dla dzieci i doros\u0142ych chorych na mukowiscydoz\u0119 oraz ich rodzic\u00f3w (CFQ-R)","volume":"84","author":"Sands","year":"2009","journal-title":"Pediatr. Pol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11136-011-0091-5","article-title":"Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample","volume":"21","author":"Quittner","year":"2012","journal-title":"Qual. Life Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Robinson","year":"2023","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Meoli, A., Fainardi, V., Deolmi, M., Chiopris, G., Marinelli, F., Caminiti, C., Esposito, S., and Pisi, G. (2021). State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090928"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e27463","DOI":"10.1002\/ppul.27463","article-title":"Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor\/Tezacaftor\/Ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clnu.2025.04.027","article-title":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"50","author":"Enaud","year":"2025","journal-title":"Clin. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107882","DOI":"10.1016\/j.rmed.2024.107882","article-title":"Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study","volume":"236","author":"Connett","year":"2025","journal-title":"Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2\u20135 Years with Cystic Fibrosis and at Least One","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two","volume":"206","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis\u2014A comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two","volume":"64","author":"Stahl","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/alr.22700","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"11","author":"DiMango","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Carnovale, V., Iacotucci, P., Terlizzi, V., Colangelo, C., Ferrillo, L., Pepe, A., Francalanci, M., Taccetti, G., Buonaurio, S., and Celardo, A. (2022). Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041021"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal Effects of Elexacaftor\/Tezacaftor\/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gruber, W., Welsner, M., Blosch, C., Dillenhoefer, S., Olivier, M., Brinkmann, F., Koerner-Rettberg, C., Sutharsan, S., Mellies, U., and Taube, C. (2023). Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy. Healthcare, 11.","DOI":"10.3390\/healthcare11212873"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/7969\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:25:05Z","timestamp":1762853105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/7969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":50,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14227969"],"URL":"https:\/\/doi.org\/10.3390\/jcm14227969","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}